Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis

Results Presented at the 2017 Annual Meeting of the American Academy of Dermatology MENLO PARK, Calif., March 8, 2017 /PRNewswire/ — Menlo Therapeutics Inc. announced today that the phase 2 trial (TCP-102) evaluating serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis successfully met its primary efficacy endpoint and key secondary endpoints, demonstrating […]

Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury

MENLO PARK, Calif., Jan. 6, 2017 /PRNewswire/ — Menlo Therapeutics Inc. (“Menlo”) has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus (itch) associated with atopic dermatitis and for the treatment of pruritus following burn injury. The ATOMIK study, MTI-103, is a […]

Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus

MENLO PARK, Calif., Jan. 5, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a clinical stage pharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant, VPD-737) for the treatment of pruritus (itch).  Over the past 16 months, Menlo Therapeutics established direct operations to advance serlopitant and recruited an experienced drug development management team including: Steven Basta, CEO. […]

Menlo Therapeutics Signs Exclusive License Agreement with Japan Tobacco and Torii Pharmaceuticals for Development and Commercialization of NK-1 receptor antagonist in Japan

MENLO PARK, Calif., Aug. 10, 2016 /PRNewswire/ — Menlo Therapeutics Inc., (Menlo Park, CA) announced today that it has entered into an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) for the development and commercialization of serlopitant in Japan. Serlopitant is a first–in-class, once-daily oral NK-1 receptor […]